AstraZeneca - PARP inhibitors in the treatment of metastatic castrate resistant prostate cancer
Exploring molecular heterogeneity in prostate cancer - prevalence and clinical significance
Date
22 Sep 2020Session
AstraZeneca - PARP inhibitors in the treatment of metastatic castrate resistant prostate cancerPresenters
Neal ShoreAuthors
N. ShoreAuthor affiliations
- Urology, Atlantic Urology Clinics, 29572 - Myrtle Beach/US
Resources
Resources from the same session
Summary and meeting close
Presenter: Neal Shore
Session: AstraZeneca - PARP inhibitors in the treatment of metastatic castrate resistant prostate cancer
Resources:
Webcast
Panel discussion
Presenter: Alexander Wyatt
Session: AstraZeneca - PARP inhibitors in the treatment of metastatic castrate resistant prostate cancer
Resources:
Webcast
Dissecting the clinical data for PARP inhibitors in metastatic castrate resistant prostate cancer
Presenter: Joaquin Mateo
Session: AstraZeneca - PARP inhibitors in the treatment of metastatic castrate resistant prostate cancer
Resources:
Webcast
Considerations for the approach to HRRm testing in prostate cancer
Presenter: Alexander Wyatt
Session: AstraZeneca - PARP inhibitors in the treatment of metastatic castrate resistant prostate cancer
Resources:
Webcast
Chair’s welcome and introductions
Presenter: Neal Shore
Session: AstraZeneca - PARP inhibitors in the treatment of metastatic castrate resistant prostate cancer
Resources:
Webcast
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.